Press Releases

2410, 2018

Groundbreaking publication in NEJM

October 24th, 2018|

Groundbreaking publication in NEJM on using DNA sequencing for drug resistance prediction in TB. For the first time, our understanding of the genetics is accurate enough to confirm that the 4 first-line drugs (isoniazid, rifampicin,


Meetings and conferences

711, 2019

Fifth Annual CRyPTIC Meeting in Hyderabad

By | November 7th, 2019|Categories: Meetings and conferences, News|0 Comments

The fifth CRyPTIC annual meeting took place in Hyderabad on Sat 26 and Sun 27 Oct 2019. Consortium partners were updated on the various analysis projects and a General Assembly was held to discuss the progress and direction of the project. Alexander Lachapelle (and Samaneh Kouchaki) updating the CRyPTIC consortium on their progress training machine learning models to predict resistance to antituberculars.

1011, 2018

Fourth Annual CRyPTIC Meeting in Dubai

By | November 10th, 2018|Categories: Meetings and conferences, News|0 Comments

The fourth annual CRyPTIC meeting took place in Dubai on 31 Oct & 1 Nov 2018 and included a meeting of the General Assembly. The majority of the meeting focussed on hearing updates from the Analysis Group on the different projects underway. Josh Carter presenting preliminary results on using machine learning to predict pyrazinamde resistance.

2804, 2017

38th Annual Congress of the European Society of Mycobacteriology

By | April 28th, 2017|Categories: Meetings and conferences|0 Comments

Ana Gibertoni Cruz and Philip Fowler will be presenting "A bespoke dry broth microdilution panel for susceptibility testing of M. tuberculosis: a validation study" and " A citizen science project helping to classify M. tuberculosis drug susceptibility testing", respectively, at ESM 2017, to take place in Croatia from 25th-28th June.


907, 2021

New publication: Structure of MmpL3 protein

By | July 9th, 2021|Categories: News|0 Comments

Oliver Adams, as part of his DPhil studies in Simon Newstead's group at the University of Oxford, has resolved the structure of MmpL3 which is the only essential member of the mmpL family of genes. It is a mycolic acid transporter that is targeted by a number of antituberculars under active development, for example SQ109 which is in Phase 3 clinical trials. This is not the first structure of MmpL3, however it is the first of the M. tuberculosis gene. The paper is now available in Structure and is free to download.

2806, 2021

WHO tuberculosis mutation catalogue released

By | June 28th, 2021|Categories: News|0 Comments

Last Friday 25 June 2021, the World Health Organization released their first report containing a catalogue of mutations in Mycobacterium tuberculosis and their association with drug resistance. The CRyPTIC project shared its large and comprehensive dataset, as well as providing its genetic processing pipeline, to the group compiling that data and producing the report. We are very pleased that even before the end of the project, the data collected and expertise gained by the project has been able to contribute in the fight to end TB.

2705, 2021

Internal project seminars in June 2021

By | May 27th, 2021|Categories: News|0 Comments

The analysis group will be presenting five consecutive seminars starting on Wed 9 June at 1500 BST (1400 GMT). Each seminar will focus on one of the primary publications to come from the CRyPTIC project. In the first seminar we will begin by describing the Release One dataset The CRyPTIC Release One dataset: how it was constructed and what is in it?Martin Hunt, Jeff Knaggs and Philip Fowler before moving on to discuss the primary publication laying out the ECOFF/ECV values derived for the UKMYC series of microtitre plates. Which MICs indicate resistance? ECOFF/ECVs for the UKMYC series of 96-well platesPhilip Fowler This is available as a preprint here and will be submitted to a journal following the seminar. If you haven't received your invitation, please contact Aysha Roohi or Philip Fowler at the University of Oxford.

2203, 2021

New preprint: Deciphering bedaquiline and clofazimine resistance in tuberculosis

By | March 22nd, 2021|Categories: News|0 Comments

Stefan Niemann, a CRyPTIC partner, led this combined experimental and modelling study looking at how resistance is conferred to bedaquline and clofazimine in Mycobacterial tuberculosis. The CRyPTIC project provided 14,151 clinical isolates, each with minimum inhibitory concentrations (MICs) to bedaquiline and clofazimine. This dataset was used to pinpoint genetic variation in Rv0678, a transcription regulator of a key efflux pump, as the main source of elevated MICs. The authors carried out evolutionary experiments on Rv0678 and were able to relate them to four major resistance mechanisms: impairment of DNA binding, reduction in protein stability, disruption of protein dimerization and reduction in affinity for its fatty acid ligand. A preprint is freely available to download. Sonnenkalb L, et al. (2021) Deciphering Bedaquiline and Clofazimine Resistance in Tuberculosis : An Evolutionary Medicine Approach. bioRxiv doi:101101/20210319436148.

203, 2021

New preprint: Establishing epidemiological cutoffs for the CRyPTIC UKMYC microdilution plates.

By | March 2nd, 2021|Categories: News|0 Comments

The CRyPTIC project has measured the minimum inhibitory concentrations (MICs) of 20,637 isolates to 13 different anti-TB drugs using a bespoke 96-well broth microdilution plate. These samples were collected by 14 partner laboratories based in 11 countries and span five continents. In this preprint, we use this large dataset to determine epidemiological cutoffs (ECOFF or ECV) for each of the 13 compounds. Although many of the analyses being undertaken by the consortium use the MIC, we also would like to be able to classify each isolate as susceptible or resistant to each of the 13 antibiotics.